← back to search

Michael F. Gerhards

OLVG · NL
Area of research
Oncology · Hepatology
Research interest
Research interests include Pancreatic and Hepatic Oncology Research, Hepatocellular Carcinoma Treatment and Prognosis, Colorectal Cancer Surgical Treatments, and Pancreatitis Pathology and Treatment.
h-index
57
citations
12,661
works
233
NIH funding
primary concept
Medicine
email

Recent publications

First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases
JAMA Oncology 2024cited by 26position: middledoi
Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group
Annals of Oncology 2024cited by 15position: middledoi
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group
The Lancet Oncology 2023cited by 166position: middledoi
Surgical outcomes of gallbladder cancer: the OMEGA retrospective, multicentre, international cohort study
EClinicalMedicine 2023cited by 55position: middledoi
Deep learning models for automatic tumor segmentation and total tumor volume assessment in patients with colorectal liver metastases
European Radiology Experimental 2023cited by 27position: middledoi
Intersurgeon Variability in Local Treatment Planning for Patients with Initially Unresectable Colorectal Cancer Liver Metastases: Analysis of the Liver Expert Panel of the Dutch Colorectal Cancer Group
Annals of Surgical Oncology 2023cited by 17position: middledoi
The role of tumour biological factors in technical anatomical resectability assessment of colorectal liver metastases following induction systemic treatment: An analysis of the Dutch CAIRO5 trial
European Journal of Cancer 2023cited by 14position: middledoi
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study.
2022cited by 27position: contributordoi
Sixty-Day Mortality of Patients With Metastatic Colorectal Cancer Randomized to Systemic Treatment vs Primary Tumor Resection Followed by Systemic Treatment
JAMA Surgery 2021cited by 53position: middledoi
The Prognostic Value of Total Tumor Volume Response Compared With RECIST1.1 in Patients With Initially Unresectable Colorectal Liver Metastases Undergoing Systemic Treatment
Annals of Surgery Open 2021cited by 18position: middledoi
Hartmann's procedure versus sigmoidectomy with primary anastomosis for perforated diverticulitis with purulent or faecal peritonitis (LADIES): a multicentre, parallel-group, randomised, open-label, superiority trial
˜The œLancet. Gastroenterology & hepatology 2019cited by 203position: middledoi
The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis
HPB 2019cited by 114position: middledoi
Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study
Surgery 2019cited by 63position: middledoi
New approach to allocation planning of many‐task workflows on clouds
Concurrency and Computation: Practice and Experience 2019cited by 1position: contributordoi
Outcomes of a Multicenter Training Program in Laparoscopic Pancreatoduodenectomy (LAELAPS-2)
Annals of Surgery 2017cited by 140position: middledoi
Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial
Trials 2015cited by 43position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Misha Luyer · Erasmus MC Cancer Institute1 papers (2017–2017) · 1 papers (2017–2017)Baki Topal · VIB-KU Leuven Center for Cancer Biology1 papers (2017–2017) · 1 papers (2017–2017)Ignace H. J. T. de Hingh · Erasmus MC Cancer Institute1 papers (2017–2017)Sebastiaan Festen · OLVG1 papers (2017–2017) · 1 papers (2017–2017)Adam Belloum · University of Amsterdam1 papers (2019–2019) · 1 papers (2019–2019)Hendrik A. Marsman · OLVG1 papers (2017–2017) · 1 papers (2017–2017)Marc G. Besselink · Cancer Genomics Centre1 papers (2017–2017)Koop Bosscha · Amsterdam University Medical Centers1 papers (2017–2017) · 1 papers (2017–2017) · 1 papers (2017–2017)Olivier R. Busch · Institut Supérieur d'Études Maritimes1 papers (2017–2017)Tom M. Karsten · OLVG1 papers (2017–2017)